Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-seq data

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Huber Keener, Kathryn J ^a   Liu, Xiuping ^b   Wang, Zhong ^a   Wang, Yaqun ^a   Freeman, Willard ^a   Wu, Song ^c   Planas Silva, Maricarmen D ^a   Ren, Xingcong ^a   Cheng, Yan ^a   Zhang, Yi ^a   Vrana, Kent ^a   Liu, Chang Gong ^b   Yang, Jin Ming ^a   Wu, Rongling ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Stony Brook University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; RNA; SMALL NUCLEOLAR RNA; TAMOXIFEN; TRANSCRIPTOME;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC PROCEDURES; HUMAN; HUMAN CELL; NEXT GENERATION SEQUENCING; PHENOTYPIC PLASTICITY; RNA SEQUENCE; RNA TRANSCRIPTION; UPREGULATION;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MCF-7 CELLS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; RNA, UNTRANSLATED; SEQUENCE ANALYSIS, RNA; TAMOXIFEN; TRANSCRIPTOME;

EID: 84864195177     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041333     Document Type: Article

References (54)

1. Harvey JM, Clark GM, Osborne CK, Allred DC, (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
2. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN, (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513-529.
3. (EBCTCG) EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
4. Hoskins JM, Carey LA, McLeod HL, (2009) CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9: 576-586.
5. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, et al. (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23: 2469-2476.
6. Shi L, Dong B, Li Z, Lu Y, Ouyang T, et al. (2009) Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 27: 3423-3429.
7. Honma N, Horii R, Iwase T, Saji S, Younes M, et al. (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26: 3727-3734.
8. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, et al. (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 12 (Suppl 1): S61-73.
9. Musgrove EA, Sutherland RL, (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643.
10. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903.
11. Tozlu-Kara S, Roux V, Andrieu C, Vendrell J, Vacher S, et al. (2007) Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. J Mol Endocrinol 39: 305-318.
12. Omoto Y, Hayashi S, (2002) A study of estrogen signaling using DNA microarray in human breast cancer. Breast Cancer 9: 308-311.
13. Masri S, Phung S, Wang X, Wu X, Yuan YC, et al. (2008) Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 68: 4910-4918.
14. Luo J, Ellis MJ, (2010) Microarray data analysis in neoadjuvant biomarker studies in estrogen receptor-positive breast cancer. Breast Cancer Res 12: 112.
15. Hurd PJ, Nelson CJ, (2009) Advantages of next-generation sequencing versus the microarray in epigenetic research. Brief Funct Genomic Proteomic 8: 174-183.
16. Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, et al. (2011) Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci U S A.
17. Gao D, Kim J, Kim H, Phang TL, Selby H, et al. (2010) A survey of statistical software for analysing RNA-seq data. Hum Genomics 5: 56-60.
18. Li Y, Alvarez OA, Gutteling EW, Tijsterman M, Fu J, et al. (2006) Mapping determinants of gene expression plasticity by genetical genomics in C. elegans. PLoS Genet 2: e222.
19. Smith EN, Kruglyak L, (2008) Gene-environment interaction in yeast gene expression. PLoS Biol 6: e83.
20. Kilker RL, Hartl MW, Rutherford TM, Planas-Silva MD, (2004) Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. J Steroid Biochem Mol Biol 92: 63-71.
21. Kilker RL, Planas-Silva MD, (2006) Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. Cancer Res 66: 11478-11484.
22. Butte AJ, Ye J, Haring HU, Stumvoll M, White MF, et al. (2001) Determining significant fold differences in gene expression analysis. Pac Symp Biocomput pp. 6-17.
23. Huang W, Umbach DM, Vincent Jordan N, Abell AN, Johnson GL, et al. (2011) Efficiently identifying genome-wide changes with next-generation sequencing data. Nucleic Acids Res 39: e130.
24. Cordero F, Botta M, Calogero RA, (2007) Microarray data analysis and mining approaches. Brief Funct Genomic Proteomic 6: 265-281.
25. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS, (1986) Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A 83: 2496-2500.
26. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH, (2007) Pathways to tamoxifen resistance. Cancer Lett 256: 1-24.
27. Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, et al. (2001) Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol 76: 71-84.
28. Akaike H, (1981) Citation Classic- a New Look at the Statistical-Model Identification. Current Contents/Engineering Technology & Applied Sciences pp. 22-22.
29. Schwarz G, (1978) Estimating the dimension of a model. Annals of Statistics 6: 461-464.
30. Dieci G, Preti M, Montanini B, (2009) Eukaryotic snoRNAs: a paradigm for gene expression flexibility. Genomics 94: 83-88.
31. Ender C, Krek A, Friedlander MR, Beitzinger M, Weinmann L, et al. (2008) A human snoRNA with microRNA-like functions. Mol Cell 32: 519-528.
32. Ofir M, Hacohen D, Ginsberg D, (2011) MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res 9: 440-447.
33. Fang L, Deng Z, Shatseva T, Yang J, Peng C, et al. (2011) MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 30: 806-821.
34. Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG, (2009) The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 11: 1208-1215.
35. Bandiera S, Ruberg S, Girard M, Cagnard N, Hanein S, et al. (2011) Nuclear outsourcing of RNA interference components to human mitochondria. PLoS One 6: e20746.
36. Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, et al. (2011) The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 18: 643-655.
37. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, et al. (1996) Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7: 351-359.
38. Cardoso CM, Custodio JB, Almeida LM, Moreno AJ, (2001) Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol 176: 145-152.
39. Shah MA, Schwartz GK, (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181.
40. Jia L, Kelsey SM, Grahn MF, Jiang XR, Newland AC, (1996) Increased activity and sensitivity of mitochondrial respiratory enzymes to tumor necrosis factor alpha-mediated inhibition is associated with increased cytotoxicity in drug-resistant leukemic cell lines. Blood 87: 2401-2410.
41. Sugai M, Umezu H, Yamamoto T, Jiang S, Iwanari H, et al. (2008) Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors. Pathol Int 58: 681-686.
42. Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, et al. (2007) Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 22: 287-298.
43. Elsheikh SE, Green AR, Rakha EA, Samaka RM, Ammar AA, et al. (2008) Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 99: 327-334.
44. Lavie Y, Fiucci G, Liscovitch M, (1998) Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 273: 32380-32383.
45. Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, et al. (2001) Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61: 1721-1733.
46. Lange CA, Yee D, (2011) Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer 18: C19-24.
47. Clarke R, (2011) Cannibalism, cell survival, and endocrine resistance in breast cancer. Breast Cancer Res 13: 311.
48. Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, et al. (2008) Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett 263: 312-320.
49. Liu M, Tang Q, Qiu M, Lang N, Li M, et al. (2011) miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells. FEBS Lett 585: 2998-3005.
50. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, et al. (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9: 239.
51. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, et al. (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23: 732-740.
52. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616.
53. Ioannidis JP, Khoury MJ, (2011) Improving validation practices in "omics" research. Science 334: 1230-1232.
54. Huang L, Zhao S, Frasor JM, Dai Y, (2011) An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS One 6: e22274.